Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation
CONCLUSION: These findings suggest that reducing the pre-infusion MRD could serve as an effective treatment strategy to enhance the outcomes of CAR T-cell therapy.PMID:38429221 | DOI:10.1016/j.clml.2024.02.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 1, 2024 Category: Cancer & Oncology Authors: Qianwen Shang Lian Xue Aidong Lu Yueping Jia YingXi Zuo Huimin Zeng Leping Zhang Source Type: research
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant
CONCLUSION: These data support the efficacy of this combination in the alloHCT relapse setting where we report responses among nearly half of patients, with possibly greater benefit for NPM1 and IDH 1/2-mutated cases. These responses can be durable and profound as evidenced by conversion to MRD negativity.PMID:38429222 | DOI:10.1016/j.clml.2024.02.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 1, 2024 Category: Cancer & Oncology Authors: Filip Ionescu Jerel C David Apoorva Ravichandran David A Sallman Kendra Sweet Rami S Komrokji Onyee Chan Andrew Kuykendall Eric Padron Rawan Faramand Nelli Bejanyan Farhad Khimani Hany Elmariah Joseph Pidala Asmita Mishra Lia Perez Taiga Nishihori Jeffrey Source Type: research
Efficacy and Safety of Children With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia After Anti-CD19 CAR T-Cell Therapy Without Bridging Transplantation
CONCLUSION: These findings suggest that reducing the pre-infusion MRD could serve as an effective treatment strategy to enhance the outcomes of CAR T-cell therapy.PMID:38429221 | DOI:10.1016/j.clml.2024.02.002 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 1, 2024 Category: Cancer & Oncology Authors: Qianwen Shang Lian Xue Aidong Lu Yueping Jia YingXi Zuo Huimin Zeng Leping Zhang Source Type: research
Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant
CONCLUSION: These data support the efficacy of this combination in the alloHCT relapse setting where we report responses among nearly half of patients, with possibly greater benefit for NPM1 and IDH 1/2-mutated cases. These responses can be durable and profound as evidenced by conversion to MRD negativity.PMID:38429222 | DOI:10.1016/j.clml.2024.02.005 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 1, 2024 Category: Cancer & Oncology Authors: Filip Ionescu Jerel C David Apoorva Ravichandran David A Sallman Kendra Sweet Rami S Komrokji Onyee Chan Andrew Kuykendall Eric Padron Rawan Faramand Nelli Bejanyan Farhad Khimani Hany Elmariah Joseph Pidala Asmita Mishra Lia Perez Taiga Nishihori Jeffrey Source Type: research
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.PMID:38403505 | DOI:10.1016/j.clml.2024.01.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 25, 2024 Category: Cancer & Oncology Authors: Oren Pasvolsky Rima M Saliba Uday R Popat Amin Alousi Rohtesh Mehta Jason Yeh Gheath Al-Atrash Masood Adeel Jeremy Ramdial David Marin Gabriela Rondon Partow Kebriaei Richard Champlin Naval Daver Courtney Dinardo Nicholas J Short Elizabeth J Shpall Bet ü Source Type: research
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.PMID:38403505 | DOI:10.1016/j.clml.2024.01.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 25, 2024 Category: Cancer & Oncology Authors: Oren Pasvolsky Rima M Saliba Uday R Popat Amin Alousi Rohtesh Mehta Jason Yeh Gheath Al-Atrash Masood Adeel Jeremy Ramdial David Marin Gabriela Rondon Partow Kebriaei Richard Champlin Naval Daver Courtney Dinardo Nicholas J Short Elizabeth J Shpall Bet ü Source Type: research
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.PMID:38403505 | DOI:10.1016/j.clml.2024.01.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 25, 2024 Category: Cancer & Oncology Authors: Oren Pasvolsky Rima M Saliba Uday R Popat Amin Alousi Rohtesh Mehta Jason Yeh Gheath Al-Atrash Masood Adeel Jeremy Ramdial David Marin Gabriela Rondon Partow Kebriaei Richard Champlin Naval Daver Courtney Dinardo Nicholas J Short Elizabeth J Shpall Bet ü Source Type: research
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.PMID:38403505 | DOI:10.1016/j.clml.2024.01.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 25, 2024 Category: Cancer & Oncology Authors: Oren Pasvolsky Rima M Saliba Uday R Popat Amin Alousi Rohtesh Mehta Jason Yeh Gheath Al-Atrash Masood Adeel Jeremy Ramdial David Marin Gabriela Rondon Partow Kebriaei Richard Champlin Naval Daver Courtney Dinardo Nicholas J Short Elizabeth J Shpall Bet ü Source Type: research
Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome
CONCLUSION: AZA maintenance was associated with a lower progression rate in patients with high-risk FLT3-negative AML or MDS, and AZA maintenance should be considered for post-alloHCT maintenance in this subset.PMID:38403505 | DOI:10.1016/j.clml.2024.01.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 25, 2024 Category: Cancer & Oncology Authors: Oren Pasvolsky Rima M Saliba Uday R Popat Amin Alousi Rohtesh Mehta Jason Yeh Gheath Al-Atrash Masood Adeel Jeremy Ramdial David Marin Gabriela Rondon Partow Kebriaei Richard Champlin Naval Daver Courtney Dinardo Nicholas J Short Elizabeth J Shpall Bet ü Source Type: research
Exploring the Therapeutic Potential of < em > Ganoderma lucidum < /em > in Cancer
J Clin Med. 2024 Feb 18;13(4):1153. doi: 10.3390/jcm13041153.ABSTRACTTriterpenoids, such as ganoderic acid, and polysaccharides, including β-D-glucans, α-D-glucans, and α-D-mannans, are the main secondary metabolites of the medicinal fungus Ganoderma lucidum. There is evidence of the effects of ganoderic acid in hematological malignancies, whose mechanisms involve the stimulation of immune response, the macrophage-like differentiation, the activation of MAP-K pathway, an IL3-dependent cytotoxic action, the induction of cytoprotective autophagy, and the induction of apoptosis. In fact, this compound has been tested in tw...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: Gabriella Cancemi Santino Caserta Sebastiano Gangemi Giovanni Pioggia Alessandro Allegra Source Type: research
Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons
Surg Oncol Clin N Am. 2024 Apr;33(2):447-466. doi: 10.1016/j.soc.2023.12.009. Epub 2024 Jan 27.ABSTRACTAlthough there are more than 100 clinically distinct lymphoid neoplasms with varied prognoses and treatment approaches, they generally share high sensitivity to glucocorticoids, cytotoxic chemotherapy, and radiation. The disease control rates for lymphoid malignancies are higher than many solid tumors, and many are curable even when presenting with extensive involvement. Novel targeted therapies have improved disease control and cure rates for nearly all subtypes of lymphoid neoplasms. Surgical oncologists will primarily ...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: William B Pearse Erin G Reid Source Type: research
Exploring the Therapeutic Potential of < em > Ganoderma lucidum < /em > in Cancer
J Clin Med. 2024 Feb 18;13(4):1153. doi: 10.3390/jcm13041153.ABSTRACTTriterpenoids, such as ganoderic acid, and polysaccharides, including β-D-glucans, α-D-glucans, and α-D-mannans, are the main secondary metabolites of the medicinal fungus Ganoderma lucidum. There is evidence of the effects of ganoderic acid in hematological malignancies, whose mechanisms involve the stimulation of immune response, the macrophage-like differentiation, the activation of MAP-K pathway, an IL3-dependent cytotoxic action, the induction of cytoprotective autophagy, and the induction of apoptosis. In fact, this compound has been tested in tw...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: Gabriella Cancemi Santino Caserta Sebastiano Gangemi Giovanni Pioggia Alessandro Allegra Source Type: research
Current Multidisciplinary Lymphoma and Myeloma Management for Surgeons
Surg Oncol Clin N Am. 2024 Apr;33(2):447-466. doi: 10.1016/j.soc.2023.12.009. Epub 2024 Jan 27.ABSTRACTAlthough there are more than 100 clinically distinct lymphoid neoplasms with varied prognoses and treatment approaches, they generally share high sensitivity to glucocorticoids, cytotoxic chemotherapy, and radiation. The disease control rates for lymphoid malignancies are higher than many solid tumors, and many are curable even when presenting with extensive involvement. Novel targeted therapies have improved disease control and cure rates for nearly all subtypes of lymphoid neoplasms. Surgical oncologists will primarily ...
Source: Clinical Lymphoma and Myeloma - February 24, 2024 Category: Cancer & Oncology Authors: William B Pearse Erin G Reid Source Type: research
Laboratory reflex testing strategy for the early identification of primary care patients with multiple myeloma
CONCLUSIONS: The above laboratory interventions agreed with clinicians, making use of laboratory technology resulted in early identification of MM.PMID:38387751 | DOI:10.1016/j.clinbiochem.2024.110730 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 22, 2024 Category: Cancer & Oncology Authors: Maria Salinas Emilio Flores Alvaro Blasco Maite Lopez-Garrig ós Ruth Torreblanca Mar ía Leiva-Salinas Irene Gutierrez Carlos Leiva-Salinas PRIMary Care-LABoratory (PRIMLAB) working group Source Type: research
Laboratory reflex testing strategy for the early identification of primary care patients with multiple myeloma
CONCLUSIONS: The above laboratory interventions agreed with clinicians, making use of laboratory technology resulted in early identification of MM.PMID:38387751 | DOI:10.1016/j.clinbiochem.2024.110730 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - February 22, 2024 Category: Cancer & Oncology Authors: Maria Salinas Emilio Flores Alvaro Blasco Maite Lopez-Garrig ós Ruth Torreblanca Mar ía Leiva-Salinas Irene Gutierrez Carlos Leiva-Salinas PRIMary Care-LABoratory (PRIMLAB) working group Source Type: research
